The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care.
The new algorithm from Implicityevaluates implantable device data and monitors patients for changes that suggest they could experience severe heart failure symptoms in the near future. It was designed to alert clinicians up to weeks in advance.
The new research, presented during ARRS 2024 in Boston, suggests CVD risk models may need to include certain findings identified in routine mammograms.
PAD patients evaluated with HeartFlow's noninvasive FFRCT Analysis technology prior to surgery experienced much better outcomes, including a 63% lower risk of all-cause mortality after five years.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."